Glenmark Pharma, USA acquires approved ANDAs from Wockhardt

28 June 2022 | News

Expands its OTC portfolio

Image Credit: Shutterstock

Image Credit: Shutterstock

Glenmark Pharmaceuticals announced that its fully owned subsidiary Glenmark Pharmaceuticals Inc, USA (Glenmark) has acquired the approved Abbreviated New Drug Applications (ANDAs) for Famotidine Tablets USP, 10 mg and 20 mg (OTC), Cetirizine Hydrochloride Tablets USP, 5 mg and 10 mg (OTC), Lansoprazole Delayed-Release Capsules USP, 15 mg (OTC) and Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 per cent (OTC) in the US from Wockhardt.

Sanjeev Krishan, President of Glenmark Pharmaceuticals, USA, said, "Our acquisition of these ANDAs
represents the continued expansion of our business into the OTC market here in the US and our commitment to ensuring patients have access to high quality, affordable medicines.”


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account